Phase II ARASEC Trial Validates NUBEQA's Efficacy in Prostate Cancer Treatment
The Phase II ARASEC trial has demonstrated that NUBEQA (darolutamide) combined with androgen deprivation therapy (ADT) significantly improves progression-free survival and overall survival in patients with metastatic castration-sensitive prostate cancer (mCSPC). The trial, which included U.S. patients, showed a 71% reduction in the risk of progression or death compared to ADT alone. These findings were presented at the American Urological Association Annual Meeting, highlighting NUBEQA's potential as an effective treatment option for mCSPC. 
